NurExone Biologic held annual shareholder meeting, votes backed all proposals

• NurExone Biologic held its annual general and special shareholder meeting on Sept. 15, 2026.
• Shareholders backed the reappointment of Ziv Haft, CPA (Isr.), a BDO member firm, as auditor for the ensuing year.
• Disinterested shareholders endorsed the amended and restated omnibus equity incentive plan.
• Investors adopted a share consolidation resolution authorizing a potential reverse split of up to 30-for-1.
• The board has discretion to implement or abandon the consolidation within 36 months; no implementation was confirmed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NurExone Biologic Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609161604PRIMZONEFULLFEED9828445) on September 16, 2026, and is solely responsible for the information contained therein.